TRAX First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance AnaptysBio, Inc. previously reported fourth-quarter and six-month 2026 results showing net income of US$183.88 million for the quarter and US$131 million for the half-year, with basic earnings per share from continuing operations rising to US$6.06 for the quarter and US$6.09 for the six months. A key driver of the very large reported profit was a US$181.5 million income-tax benefit from releasing a deferred-tax valuation allowance following the separation of First Tracks Biotherapeutics, an... | ||
 AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns? AnaptysBio, Inc. (NASDAQ:ANAB) reported $176.4 million of income from continuing operations for the six months ended June 30 in results released September 21. A $181.5 million income-tax benefit, primarily from releasing a deferred-tax valuation allowance, turned a $5.1 million pretax loss into that profit. The tax adjustment reflects greater expected use of tax assets following […] | ||